Trial Profile
Evaluation of the Clinic Efficacy of Immunoglobulin Anti-RhD KamRho-D® (Panamerican) in Postpartum Immunization of Rh and Coombs Negative Women at Sensitization Risk
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2022
Price :
$35
*
At a glance
- Drugs Anti-D Rh0 immunoglobulin (Primary) ; Immune globulin
- Indications Haemolytic disease of newborn
- Focus Therapeutic Use
- 17 Aug 2018 Planned number of patients changed from 232 to 347.
- 17 Aug 2018 Planned End Date changed from 1 Nov 2017 to 1 Dec 2020.
- 17 Aug 2018 Status changed from recruiting to suspended for indetermined period.